Emerging drugs for adrenocortical carcinoma

Alfredo Berruti University of Turin, Department of Clinical and Biological Science, Oncologia Medica, Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Italy +39 0119026512; +39 0119026992; [email protected]

Anna Ferrero University of Turin, Department of Clinical and Biological Science, Oncologia Medica, Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Italy +39 0119026512; +39 0119026992; [email protected]

Paola Sperone University of Turin, Department of Clinical and Biological Science, Oncologia Medica, Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Italy +39 0119026512; +39 0119026992; [email protected]

Fulvia Daffara Medicina Interna, Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy +39 0119026427; +39 0119026992; [email protected]

Giuseppe Reimondo Medicina Interna, Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy +39 0119026427; +39 0119026992; [email protected]

Mauro Papotti Anatomia Patologica, Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy +39 0119026486; +39 0119026992; [email protected]

Luigi Dogliotti University of Turin, Department of Clinical and Biological Science, Oncologia Medica, Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Italy +39 0119026512; +39 0119026992; [email protected]

Alberto Angeli Medicina Interna, Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy +39 0119026427; +39 0119026992; [email protected]

Massimo Terzolo Medicina Interna, Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy +39 0119026427; +39 0119026992; [email protected]

show all

Abstract

Background: Adrenocortical carcinoma (ACC) is an extremely rare aggressive disease. Few data are available on the efficacy of systemic antineoplastic treatments (mitotane and cytotoxic therapy) in the treatment of advanced disease. Objective/methods: this paper will review the existing treatment strategies and new perspectives in the management of ACC patients. Results/conclusion: An ongoing randomized international trial aims to define the best combination chemotherapy plus mitotane regimen. Based on the results of a case control study, mitotane is being explored as adjuvant therapy. Genetic and biological studies have identified molecular targets for specific targeted drugs such as IGF receptor inhibitors and antiangiogenetic drugs. Phase II trials are exploring the activity of these drugs either alone or in combination with chemotherapy.

Keywords::

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Emerging drugs for adrenocortical carcinoma

Information for

Open access

Opportunities

Help and information

Emerging drugs for adrenocortical carcinoma

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature